BioSpace News Archive

Y-mAbs Therapeutics, Inc. announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with relapsed or refractory high-risk neuroblastoma with residual disease limited to bone and/or bone marrow.

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development

Jazz Pharmaceuticals plc announced long-term follow-up results, including the first-ever overall survival findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer.

Y-mAbs Therapeutics, Inc. announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.

Genmab A/S and BioNTech SE announced initial data from the ongoing Phase 2 trial evaluating acasunlimab, an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L-positive metastatic non-small cell lung cancer who had disease progression following one or more prior lines of anti-PD1-containing treatment.

Affimed N.V. announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the presentation of updated exploratory subgroup analyses from the SIENDO study, in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology Annual Meeting.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life.